Results 41 to 50 of about 10,911,887 (292)

Duodenal biopsy: an unexpected confirmatory test for a patient with al-amyloidosis

Sri Lanka Journal of Medicine, 2019
SSystemic AL- amyloidosis is a disorder of protein folding in which there is extra-cellular accumulation as β pleated fibrillar deposits of monoclonal immunoglobulin light chain fragments. AL- amyloidosis is a rare clinical entity.
S. Pirasath, T. Kumanan, G. Selvaratnam, V. Sujanitha, D. D. Dikowita   +4 more
doaj   +1 more source

Hemostasis disorders in patients with systemic AL-amyloidosis

Терапевтический архив, 2023
Aim. To analyze the frequency and nature of hemorrhagic and thrombotic complications in patients with systemic AL-amyloidosis and compare with laboratory changes in the hemostasis system. Materials and methods.
Irina G. Rekhtina, Victoria A. Khyshova, Nadezhda I. Zozulya, Valentina N. Dvirnyk, Larisa P. Mendeleyeva   +4 more
doaj   +1 more source

Daratumumab for the treatment of AL amyloidosis [PDF]

Leukemia & Lymphoma, 2018
Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, and immunotherapy with monoclonal ...
M. Hasib Sidiqi, Morie A. Gertz
openaire   +2 more sources

Real‐World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild‐Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records

eJHaem
Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate ...
Muhamed Baljevic, Haechung Chung, Jose Alvir, Patrick Feron, Aaron Crowley, Darrin Benjumea, Yong Chen, Cindi Pankratova   +7 more
doaj   +1 more source

Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study

Cancer Management and Research, 2021
Junhui Xu,* Mangju Wang,* Ye Shen, Miao Yan, Weiwei Xie, Bingjie Wang, Huihui Liu, Xinan Cen Department of Hematology, Peking University First Hospital, Beijing, People’s Republic of China*These authors contributed equally to this ...
Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, Liu H, Cen X   +7 more
doaj  

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Impact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis

Клиническая онкогематология
AIM. To assess the clinical features as well as the factors affecting prognosis and long-term treatment outcomes in systemic AL amyloidosis patients with cardiac involvement. MATERIALS & METHODS. The trial enrolled 123 systemic AL amyloidosis patients
Olga Vladislavovna Pirogova, O. V. Kudyasheva, M. V. Chernous, M. A. Gorodnova, D. K. Lamden, K. A. Novitskaya, A. G. Smirnova, A. V. Yakovleva, V. A. Ionin, A. M. Ananin, I. S. Moiseev, A. D. Kulagin   +11 more
doaj   +1 more source

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker Research, 2023
Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart   +8 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Localized AL amyloidosis

Terapevticheskii arkhiv
Localized light chain (AL) amyloidosis (amyloidoma) is a rare disease with unclear pathogenesis and undeveloped approaches to therapy. This article presents 3 clinical observations of localized AL amyloidosis with lesions of the respiratory tract, eyes, and soft tissues of the face.
Nelly A. Kashchavtseva, Irina G. Rekhtina, Alla M. Kovrigina, Tatyana P. Danilina, Larisa P. Mendeleeva   +4 more
openaire   +3 more sources